Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.65 |
| ▸ | LCK | P06239 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 4/20 | 0.55 |
| ▸ | MAOA | P21397 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.49 |
| ▸ | NQO2 | P16083 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
| ▸ | BACE1 | P56817 | 2/20 | 0.47 |
| ▸ | TLR4 | O00206 | 1/20 | 0.46 |
| ▸ | TLR2 | O60603 | 1/20 | 0.46 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | CDK4 | P11802 | 1/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.46 |
| ▸ | CCND1 | P24385 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3679466 | 1.00 | CYP1A1 (0.65) | CYP1A1CYP1A2CYP19A1LCKMAOB | |
| SCHEMBL3679961 | 0.84 | CYP1A1 (0.56) | CYP1A1CYP1A2CYP19A1LCKMAOB | |
| SCHEMBL3679964 | 0.84 | CYP1A1 (0.56) | CYP1A1CYP1A2CYP19A1LCKMAOB | |
| SCHEMBL6308482 | 0.83 | LCK (0.77) | CYP1A1CYP1A2CYP19A1LCKMAOB | |
| SCHEMBL3650797 | 0.83 | LCK (0.77) | CYP1A1CYP1A2CYP19A1LCKMAOB | |
| SCHEMBL3650792 | 0.83 | LCK (0.77) | CYP1A1CYP1A2CYP19A1LCKMAOB | |
| SCHEMBL28441803 | 0.82 | CYP1A2 (0.73) | CYP1A1CYP1A2CYP19A1LCKMAOB | |
| SCHEMBL3242914 | 0.82 | MAOB (0.65) | CYP1A1CYP1A2CYP19A1LCKMAOB | |
| SCHEMBL5042093 | 0.81 | ALOX5 (0.55) | CYP1A1CYP1A2CYP19A1MAOBMAOA | |
| SCHEMBL31160636 | 0.81 | MEN1 (0.59) | CYP1A2MAOBMAOAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753708-B1 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS FOR MAKING THE SAME | UNIV BRIGHAM YOUNG (US) | 2018-02-21 | — | — | EP | disclosed |
| US-8841477-B2 | Sirtuin activating compounds and processes for making the same | BRIGHAM YOUNG UNIVERSITY (US) | 2014-09-23 | — | — | US | disclosed |
| US-20100185006-A1 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND PROCESSES FOR MAKING THE SAME | BRIGHAM YOUNG UNIVERSITY (US) | 2010-07-22 | — | — | US | disclosed |
| US-7714161-B2 | N-heterocyclic carbon-type ligand coupling in the presence of a base with benzyol halide and styrene coupling partners; resveratrol; increased stability for use in the food, cosmetic and pharmaceutical industries | BRIGHAM YOUNG UNIVERSITY (US) | 2010-05-11 | — | — | US | disclosed |
| US-20080255382-A1 | N-heterocyclic carbon-type ligand coupling in the presence of a base with benzyol halide and styrene coupling partners; resveratrol; increased stability for use in the food, cosmetic and pharmaceutical industries | BRIGHAM YOUNG UNIVERSITY | 2008-10-16 | — | — | US | disclosed |
| EP-1753708-A4 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS FOR MAKING THE SAME | UNIV BRIGHAM YOUNG (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1753708-A2 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS FOR MAKING THE SAME | Brigham Young University (US) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005069998-A2 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS FOR MAKING THE SAME | BRIGHAM YOUNG UNIVERSITY TECHNOLOGY TRANSFER OFFICE (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100185006-A1 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND PROCESSES FOR MAKING THE SAME | SIRT1, SIRT2, SIRT3 | CYP1A1 743/4885CYP1A2 1138/4885CYP19A1 340/4885 |
| US-20080255382-A1 | N-heterocyclic carbon-type ligand coupling in the presence of a base with benzyol halide and styrene coupling partners; resveratrol; increased stability for use in the food, cosmetic and pharmaceutical industries | RB1, SBK1, NADK | CYP1A1 772/4885CYP1A2 1064/4885CYP19A1 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.